# A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

> **NCT06372574** · PHASE1 · WITHDRAWN · sponsor: **Genentech, Inc.**

## Conditions studied

- Refractory Cancer
- Recurrent Cancer
- Solid Tumor, Adult

## Interventions

- **DRUG:** RO7617991
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT06372574
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-09-30
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** GO44669 study has been withdrawn due to an internal Sponsor decision. The decision was not due to any safety or efficacy concerns with the study drug.
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06372574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06372574, "A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06372574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*